Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Liu, Xiaochen ^a   Lin, Zhirong ^a   Zhou, Tong ^a   Zong, Ronrong ^a   He, Hui ^a   Liu, Zhen ^a   Ma, Jian Xing ^b   Liu, Zuguo ^a   Zhou, Yueping ^a  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERINE PROTEINASE INHIBITOR; SERPINA3K; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANGIOGENESIS MODULATOR; ANTIINFLAMMATORY AGENT; AUTACOID; SERPINA3K PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROTEIN PURIFICATION; PURIFICATION; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; CORNEA; CORNEA NEOVASCULARIZATION; DRUG EFFECT; EYE BURN; INFLAMMATION; INJURY; PATHOLOGY; VASCULARIZATION;

RATTUS;

ANGIOGENESIS INHIBITORS; ANGIOGENESIS MODULATING AGENTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CORNEA; CORNEAL NEOVASCULARIZATION; EYE BURNS; GENE EXPRESSION REGULATION; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, ANIMAL; RATS; SERPINS;

EID: 79551623126     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016712     Document Type: Article

References (35)

1. Khaw PT, Shah P, Elkington AR (2004) Injury to the eye. BMJ 328: 36-8.
2. Kuo IC (2004) Corneal wound healing. Curr Opin Ophthalmol 15: 311-5.
3. Adamis AP, Aiello LP, D'Amato RA (1999) Angiogenesis and ophthalmic disease. Angiogenesis 3: 9-14.
4. Miller JW (1997) Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 151: 13-23.
5. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28: 488-94.
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
7. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489: 270-276.
8. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, et al. (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285: 245-258.
9. King GL, Suzuma K (2000) Pigment-epithelium-derived factor-α key coordinator of retinal neuronal and vascular functions. N Engl J Med 342: 349-351.
10. Jenkins A, Zhang SX, Gosmanova A, Aston C, Dashti A, et al. (2008) Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Res Clin Pract 82: e5-7.
11. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, et al. (2006) Pigment epitheliumderived factor (PEDF) is an endogenous antiinflammatory factor. Faseb J 20: 323-325.
12. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, et al. (2004) Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A 101: 6605-6610.
13. Spranger J, Osterhoff M, Reimann M,Mohlig M, Ristow M, et al. (2001) Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50: 2641-2645.
14. Wang JJ, Zhang SX, Mott R, Chen Y, Knapp RR, et al. (2008) Antiinflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol 294: F1166-1173.
15. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, et al. (2001) Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188: 253-263.
16. Zhou GX, Chao L, Chao J (1992) Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267: 25873-25880.
17. Chai KX, Ma J-X, Murray SR, Chao J, Chao L (1991) Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem 266: 16029-16036.
18. Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102: 4751-4804.
19. Chao J, Chai KX, Chen LM, Xiong W, Chao S, et al. (1990) Tissue kallikreinbinding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 265: 16394-16401.
20. Gao G, Shao C, Zhang SX, Dudley A, Fant J, et al. (2003) Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 46: 689-698.
21. Zhang B, Hu Y, Ma JX (2009) Anti-inflammatory and antioxidant effects of SERPINA3K in the retina. Invest Ophthalmol Vis Sci 50: 3943-52.
22. Zhang B, Ma JX (2008) SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload. PLoS One 3: e4077.
23. Zhang B, Abreu JG, Zhou K, Chen Y, Hu Y, et al. (2010) Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci U S A 107: 6900-5.
24. Zhang Z, Ma JX, Gao G, Li C, Luo L, et al. (2005) Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization. Invest Ophthalmol Vis Sci 46: 4062-4071.
25. Laria C, Alio JL, Ruiz-Moreno JM (1997) Combined non-steroidal therapy in experimental corneal injury. Ophthalmic Res 29: 145-153.
26. Pauly A, Brignole-Baudouin F, Labbe A, Liang H, Warnet JM, et al. (2007) New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci 48: 5473-5483.
27. Bressler NM (2009) Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 116: S15-23.
28. Horsley MB, Kahook MY (2010) Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 21: 112-7.
29. Michalova K, Lim L (2008) Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep 8: 339-47.
30. Navarro-González JF, Mora-Fernández C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-42.
31. Fornoni A, Ijaz A, Tejada T, Lenz O (2008) Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 4: 10-7.
32. Schneider MR, Wolf E (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218: 460-6.
33. Yu FS, Yin J, Xu K, Huang J (2010) Growth factors and corneal epithelial wound healing. Brain Res Bull 81: 229-35.
34. Webler AC, Michaelis UR, Popp R, Barbosa-Sicard E, Murugan A, et al. (2008) Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol 295: C1292-301.
35. Heo SH, Choi YJ, Ryoo HM, Cho JY (2010) Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGFinduced angiogenesis. J Cell Physiol 224: 734-42.